ZA983497B - Activated protein c formulations. - Google Patents

Activated protein c formulations.

Info

Publication number
ZA983497B
ZA983497B ZA9803497A ZA983497A ZA983497B ZA 983497 B ZA983497 B ZA 983497B ZA 9803497 A ZA9803497 A ZA 9803497A ZA 983497 A ZA983497 A ZA 983497A ZA 983497 B ZA983497 B ZA 983497B
Authority
ZA
South Africa
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Application number
ZA9803497A
Other languages
English (en)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA983497B publication Critical patent/ZA983497B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA9803497A 1997-04-28 1998-04-24 Activated protein c formulations. ZA983497B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
ZA983497B true ZA983497B (en) 1999-10-25

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9803497A ZA983497B (en) 1997-04-28 1998-04-24 Activated protein c formulations.
ZA9803496A ZA983496B (en) 1997-04-28 1998-04-24 Methods for processing activated protein C.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA9803496A ZA983496B (en) 1997-04-28 1998-04-24 Methods for processing activated protein C.

Country Status (34)

Country Link
US (4) US6162629A (en, 2012)
EP (2) EP0875252B1 (en, 2012)
JP (2) JP4383546B2 (en, 2012)
KR (2) KR100450856B1 (en, 2012)
CN (2) CN1235638C (en, 2012)
AR (2) AR015598A1 (en, 2012)
AT (1) ATE285788T1 (en, 2012)
AU (2) AU743531B2 (en, 2012)
BR (2) BR9809304B1 (en, 2012)
CA (2) CA2287267C (en, 2012)
CO (2) CO4940438A1 (en, 2012)
CZ (1) CZ298429B6 (en, 2012)
DE (1) DE69828330T2 (en, 2012)
DK (1) DK0875252T3 (en, 2012)
EA (2) EA004881B1 (en, 2012)
EG (1) EG23685A (en, 2012)
ES (1) ES2234072T3 (en, 2012)
HU (2) HU224826B1 (en, 2012)
ID (2) ID23172A (en, 2012)
IL (2) IL132325A (en, 2012)
IN (2) IN187157B (en, 2012)
MY (2) MY118591A (en, 2012)
NO (2) NO995134L (en, 2012)
NZ (2) NZ500346A (en, 2012)
PE (2) PE86299A1 (en, 2012)
PL (2) PL195642B1 (en, 2012)
PT (1) PT875252E (en, 2012)
SI (1) SI0875252T1 (en, 2012)
SV (2) SV1998000051A (en, 2012)
TR (2) TR199902631T2 (en, 2012)
TW (2) TW585871B (en, 2012)
UA (2) UA73071C2 (en, 2012)
WO (2) WO1998048818A1 (en, 2012)
ZA (2) ZA983497B (en, 2012)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4383546B2 (ja) 1997-04-28 2009-12-16 イーライ・リリー・アンド・カンパニー 活性化プロテインｃの改良プロセシング方法
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CA2351067A1 (en) * 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
ES2192874T3 (es) * 1998-11-23 2003-10-16 Lilly Co Eli Proteina c para el tratamiento de la enfermedad de la celula con anemia hepatica y talasemia.
IL142249A0 (en) * 1998-12-10 2002-03-10 Lilly Co Eli Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US7430476B2 (en) 2001-02-19 2008-09-30 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
DK1517698T4 (da) 2002-06-21 2018-01-29 Novo Nordisk Healthcare Ag Stabiliserede faste sammensætninger af Faktor VIIa-polypeptider
MXPA05004593A (es) * 2002-10-29 2005-07-26 Alza Corp Particulas de polipeptido estabilizado en estado solido.
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
PT2029740E (pt) * 2006-05-31 2012-07-06 Genzyme Corp Utilização de polissacáridos para promoção de actividade enzimática
CA2654761A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
TW200938221A (en) * 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9357765B2 (en) 2012-04-03 2016-06-07 Smiths Medical Asd, Inc. Heparain-bulking agent compositions and methods thereof
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2015246656B2 (en) 2014-04-16 2020-06-18 Zz Biotech Llc Use of APC analogue for wound healing
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
HUE057856T2 (hu) * 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
JP4383546B2 (ja) * 1997-04-28 2009-12-16 イーライ・リリー・アンド・カンパニー 活性化プロテインｃの改良プロセシング方法
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
US6162629A (en) 2000-12-19
SI0875252T1 (en) 2005-06-30
CA2287267A1 (en) 1998-11-05
EP0875252B1 (en) 2004-12-29
DE69828330T2 (de) 2005-10-13
MY120984A (en) 2005-12-30
PE86299A1 (es) 1999-09-17
JP4383547B2 (ja) 2009-12-16
AU740753C (en) 2002-10-10
TWI242443B (en) 2005-11-01
EA002149B1 (ru) 2001-12-24
NO995198D0 (no) 1999-10-25
EA199900980A1 (ru) 2000-04-24
ZA983496B (en) 1999-10-25
EA199900979A1 (ru) 2000-06-26
UA55448C2 (uk) 2003-04-15
HUP0100284A2 (hu) 2001-06-28
CZ298429B6 (cs) 2007-10-03
UA73071C2 (en) 2005-06-15
NZ500346A (en) 2001-08-31
US6159468A (en) 2000-12-12
PL195642B1 (pl) 2007-10-31
IL132502A0 (en) 2001-03-19
DK0875252T3 (da) 2005-04-25
CN1254284A (zh) 2000-05-24
PL336889A1 (en) 2000-07-17
IN183798B (en, 2012) 2000-04-15
AU7161898A (en) 1998-11-24
CA2288143C (en) 2012-08-21
BR9809304A (pt) 2000-10-17
NO995134L (no) 1999-12-21
CA2287267C (en) 2006-08-15
PL195090B1 (pl) 2007-08-31
IL132325A0 (en) 2001-03-19
TW585871B (en) 2004-05-01
TR199902529T2 (xx) 2000-02-21
HUP0003401A3 (en) 2003-01-28
TR199902631T2 (xx) 2000-01-21
DE69828330D1 (de) 2005-02-03
HU224826B1 (en) 2006-02-28
ID22933A (id) 1999-12-16
SV1998000050A (es) 1999-01-13
PT875252E (pt) 2005-03-31
JP2001524111A (ja) 2001-11-27
ID23172A (id) 2000-03-23
US6436397B1 (en) 2002-08-20
EG23685A (en) 2007-05-09
WO1998048818A1 (en) 1998-11-05
EP0875563A3 (en) 2000-08-02
AU7258998A (en) 1998-11-24
AR012010A1 (es) 2000-09-13
CN1261280A (zh) 2000-07-26
EP0875252A3 (en) 2000-07-26
MY118591A (en) 2004-12-31
AR015598A1 (es) 2001-05-16
CA2288143A1 (en) 1998-11-05
HUP0003401A2 (hu) 2001-02-28
CZ381099A3 (cs) 2000-03-15
AU743531B2 (en) 2002-01-31
EP0875563A2 (en) 1998-11-04
NO995134D0 (no) 1999-10-21
EA004881B1 (ru) 2004-08-26
PE84799A1 (es) 1999-09-16
EP0875252A2 (en) 1998-11-04
HK1016472A1 (en) 1999-11-05
KR20010020325A (ko) 2001-03-15
CO4940438A1 (es) 2000-07-24
PL336420A1 (en) 2000-06-19
SV1998000051A (es) 1998-12-11
BR9809292A (pt) 2000-07-04
CN1235638C (zh) 2006-01-11
JP4383546B2 (ja) 2009-12-16
CN1227025C (zh) 2005-11-16
JP2001527543A (ja) 2001-12-25
CO4950523A1 (es) 2000-09-01
KR100450856B1 (ko) 2004-10-02
IN187157B (en, 2012) 2002-02-16
US6395270B1 (en) 2002-05-28
WO1998048822A1 (en) 1998-11-05
BR9809304B1 (pt) 2011-02-08
NO995198L (no) 1999-10-25
NZ337828A (en) 2001-06-29
AU740753B2 (en) 2001-11-15
IL132325A (en) 2005-07-25
KR100564189B1 (ko) 2006-03-27
HUP0100284A3 (en) 2003-08-28
KR20010020242A (ko) 2001-03-15
ATE285788T1 (de) 2005-01-15
ES2234072T3 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
ZA983497B (en) Activated protein c formulations.
ZA987844B (en) Therapeutic combinations.
ZA9811849B (en) Vaccine.
ZA984969B (en) Vaccine.
ZA988789B (en) Vaccine.
EP1113799A4 (en) PROTEIN-BASED PREPARATION
ZA982253B (en) Therapeutic compositions.
ZA966075B (en) Protein formulation.
ZA981029B (en) Pharmaceutical agents.
ZA9811504B (en) Novel pharmaceutical.
ZA9811506B (en) Novel pharmaceutical.
ZA989680B (en) Pharmaceutical composition.
ZA9811505B (en) Novel pharmaceutical.
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
ZA987392B (en) Pharmaceutical composition.
GB9715064D0 (en) Protein expression
ZA983705B (en) Pregnan-3-ol-20-ones.
GB9720784D0 (en) Protein
ZA968185B (en) Protein.
ZA988206B (en) Piperidinylmethyloxazolidinone derivative.
ZA982558B (en) Novel Pharmaceutical.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
ZA983698B (en) Estrenes.
ZA9811834B (en) Substititued ß-alanines.